Latest Breaking News On - Marina kremyanskaya - Page 1 : vimarsana.com

Rusfertide Treatment Beneficial for Patients With Polycythemia Vera

Rusfertide reduces number of phlebotomies and maintains hematocrit at less than 45%

Rusfertide More Than Triples Responses Vs Placebo in Phlebotomy-Dependent Polycythemia Vera

Rusfertide displayed activity in phlebotomy-dependent polycythemia vera.

New Drug Rusfertide Shows Promise in Treating Polycythemia Vera, Revealing Positive Outcomes

Polycythemia vera falls under the category of chronic myeloproliferative neoplasms, which disrupt the normal production of blood cells within the bone marrow.

Rusfertide Treatment Beneficial for Patients With Polycythemia Vera

Rusfertide reduces number of phlebotomies and maintains hematocrit at less than 45%.

New Drug May Decrease Need for Blood Draws in Patients With PV

Treatment with rusfertide led to a decrease in the need for blood draws and decreased levels of red blood cells in patients with polycythemia vera.

REVIVE: ​​Rusfertide Effective for Erythrocytosis Control in Polycythemia Vera

Rusfertide maintained a hematocrit of <45% and reduced or eliminated the use of phlebotomy in patients with polycythemia vera.

A Mount Sinai-Led Study Shows Early Success of a Novel Drug in Treating a Rare and Chronic Blood Cancer

Results of 16-Center REVIVE trial published in The New England Journal of Medicine

Study shows early success of a novel drug in treating a rare and chronic blood cancer

Novel Drug Shows Early Promise in Rare Blood Cancer Study

CURE Media Group announces winners of the 2023 MPN Heroes® Recognition Program